Last week, Cassava announced that it had completed the third interim safety review of simufilam in ongoing late-stage studies for Alzheimer's disease patients. Following a routine scheduled meeting, the Data and Safety Monitoring Board (DSMB) recommended that both phase III Alzheimer's studies of the candidate continue as planned without modification. Management stated that the latest DSMB safety review was the last before the expected top-line readout for the RETHINK-ALZ study.